Many previous studies focusing on ER-positive breast cancer have found high cyclin D1 expression or gene amplification to be an adverse prognostic sign [5, 7, 11, 18, 42, 44, 50], while the results in ER-negative and in unselected breast cancer patients have been highly inconsistent. This evidence concerns the gene CCND1 and breast carcinoma.